Health Catalyst beats Q3 guidance; raises FY2023 revenue outlook; Adj. EBITDA positive

Health Catalyst, Inc.

2023-Q3 EPS reported -$1.57 revenue$220,854,000

Q3 total revenue $73.8M (+8% YoY), above guidance midpoint; net loss $22.0M vs $45.7M loss in Q3 2022.
Adjusted EBITDA $2.0M (improvement from -$4.6M YoY), also above guidance midpoint of $1.25M.
Raised FY2023 revenue guidance to $291M-$296M from $290.5M-$295.5M; reiterated Adj. EBITDA $10M-$12M.
New DOS client: Accountable Health Partners (~400k patients); Q4 expected to be a large bookings quarter.
Mid-term targets: revenue reacceleration in 2024, 10% Adj. EBITDA margin in 2025, long-term 20%+ growth.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

Health Catalyst, Inc. reported the quarter ended September 30, 2023 results: revenue $73.8 million, net income $(22,032) thousand. Guidance raised.

Period: the quarter ended September 30, 2023
Revenue: $73.8 million
Net income: $(22,032) thousand
Guidance: raised
Result: reported results

Exact text from the filing

reported financial results for the quarter ended September 30, 2023. “For the third quarter of 2023, I am pleased by our strong financial results, including total revenue of $73.8 million and Adjusted EBITDA of $2.0 million, with these results beating the mid-point of our quarterly guidance on each metric. Additionally, we are grateful to be in a position to raise

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Health Catalyst, Inc. filing history →

Source: SEC EDGAR

accession 0001636422-23-000129

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.